Participants needed for nationwide Semaglutide audit
Healthcare professionals are being urged to take part in a nationwide audit about Semaglutide.
The Association of British Clinical Diabetologists (ABCD) launched the survey following on from the success of previous ABCD audits of GLP1 receptor agonists, SGLT2 inhibitors, insulin degludec, IDegLira and most recently the FreeStyle Libre.
A spokesperson for the organisation said: “As Semaglutide is now on most formularies, ABCD would like to encourage you to join in the nationwide audit.”
Clinical trials involving Semaglutide have suggested that it is more effective than the other GLP-1 receptor agonists. The idea of the audit is to find out the extent to which the experience in clinical trials translates into the real world.
However, there are many questions that ABCD is seeking answers for such as how people who switch from another GLP-1 receptor agonist to Semaglutide are impacted.
They also want to know whether there are any other factors that will predict good response and poor response and is the impact on insulin requirement when a person starts taking the drug.
ABCD said is it easy for users to analyse their own results using the organisation’s online Semaglutide audit tool, which features in this simple how to do it video tutorial. Some Clinical Commissioning Groups (CCG) are requesting local audit and the tool facilitates this.
Forms for handwritten data entry, that match the online tool, can be downloaded from the semaglutide audit webpage.
Participants do not have to be ABCD members and all contributors will be acknowledged in all papers and presentations from the audit data. Larger contributors will be offered the possibility of being co-authors.